Q-VD-OPh: Irreversible Pan-Caspase Inhibitor for Apoptosis Research

Executive Summary: Q-VD-OPh (CAS 1135695-98-5) is a potent, cell-permeable, and irreversible pan-caspase inhibitor used extensively in apoptosis research (Sekar et al., 2022, DOI). It targets caspase-1, -3, -8, and -9 with IC₅₀ values of approximately 50 nM, 25 nM, 100 nM, and 430 nM, respectively (APExBIO). Q-VD-OPh blocks both intrinsic (caspase-9/3) and extrinsic (caspase-8/10) apoptotic pathways, thereby preventing cell death in response to various stimuli. Its high selectivity and brain permeability make it invaluable for both in vitro and in vivo studies, including neurodegenerative disease models. The compound remains stable at ≤ -20°C for several months and is not suitable for long-term solution storage (Product Sheet).

Biological Rationale

Programmed cell death (apoptosis) is a critical physiological process regulating tissue homeostasis and response to cellular stress (Sekar et al., 2022). The caspase family of cysteine proteases executes apoptosis through intracellular proteolysis, dismantling cells in a tightly controlled cascade. Dysregulation of apoptosis is implicated in cancer, neurodegeneration, and immune disorders. Caspase inhibitors such as Q-VD-OPh are instrumental for dissecting apoptotic signaling, validating therapeutic targets, and preserving cellular integrity under experimental stress. Notably, Q-VD-OPh’s cell- and brain-permeability enable studies across diverse species and tissues, including human, mouse, and rat models (Q-VD-OPh: Pan-Caspase Inhibitor for Advanced Apoptosis Research).

Mechanism of Action of Q-VD-OPh

Q-VD-OPh irreversibly inhibits caspases by covalently binding to their catalytic cysteine residues. Its core structure enables high-affinity, irreversible interaction with both initiator and executioner caspases, including caspase-1, -3, -8, and -9 (APExBIO). This broad-spectrum inhibition prevents cleavage of downstream apoptotic substrates and blocks both intrinsic (mitochondrial, caspase-9/3) and extrinsic (death receptor, caspase-8/10) apoptotic pathways. Q-VD-OPh also inhibits caspase-12, implicated in endoplasmic reticulum stress response. Its design overcomes limitations of earlier caspase inhibitors by improving cell and brain permeability and reducing off-target toxicity (Q-VD-OPh: Irreversible Pan-Caspase Inhibitor for Apoptosis Research). This article extends previous reviews by detailing irreversible inhibition kinetics, specific IC₅₀ values, and comparative selectivity.

Evidence & Benchmarks

• Q-VD-OPh inhibits caspase-3 with an IC₅₀ of ~25 nM in cell-free assays at 25°C, pH 7.4 (APExBIO product data).
• Irreversible binding to the caspase catalytic cysteine confirmed by mass spectrometry and activity-based profiling (Sekar et al., 2022, DOI).
• Q-VD-OPh at 10 μM prevents actinomycin D-induced apoptosis in HeLa cells, as measured by annexin V/PI staining after 24 h at 37°C (Q-VD-OPh: Unlocking Mitochondrial Apoptosis Insights).
• In vivo, Q-VD-OPh administered intraperitoneally at 10 mg/kg thrice weekly for 3 months inhibits caspase-7 activation and mitigates tau pathology in murine Alzheimer’s disease models (APExBIO).
• Q-VD-OPh enhances cell viability by 40–60% during thawing from cryopreservation in standard DMSO/FBS conditions (8% DMSO, -196°C to 37°C, 5 min recovery; see details).

Applications, Limits & Misconceptions

Q-VD-OPh is used to delineate caspase-dependent cell death in basic and translational research. Its applications span cancer biology, neurodegeneration, immunology, and cryopreservation. The compound is frequently used to distinguish apoptosis from necrosis or other forms of programmed cell death, such as pyroptosis or necroptosis (Q-VD-OPh: A Next-Generation Pan-Caspase Inhibitor). This article clarifies the selectivity and irreversible action of Q-VD-OPh compared to earlier reversible inhibitors.

Common Pitfalls or Misconceptions

• Q-VD-OPh is not effective against non-caspase proteases or forms of cell death independent of the caspase cascade (e.g., necroptosis, ferroptosis).
• It does not reverse established cell death; it prevents initiation of caspase-mediated apoptosis.
• Q-VD-OPh is insoluble in water; use DMSO or ethanol for stock solutions (≥25.67 mg/mL in DMSO, ≥28.75 mg/mL in ethanol).
• Prolonged storage of diluted solutions (even at -20°C) may reduce potency due to hydrolysis; prepare fresh stocks as needed.
• Q-VD-OPh is intended for research use only; not for diagnostic or medical purposes.

Workflow Integration & Parameters

Q-VD-OPh is supplied as a solid by APExBIO under SKU A1901 (Q-VD-OPh product page). For in vitro use, dissolve in DMSO or ethanol to obtain a working stock (typical final concentration 1–50 μM). Store stock solutions at ≤ -20°C. For in vivo studies, intraperitoneal administration at 10 mg/kg thrice weekly is supported by murine neurodegeneration models. Q-VD-OPh can be co-administered with standard cryoprotectants to enhance post-thaw viability. For mechanistic studies, pair Q-VD-OPh treatment with downstream readouts such as caspase activity assays, annexin V staining, or Western blot for cleaved PARP.

For a deep-dive into imaging applications and mitochondrial mRNA dynamics, see Q-VD-OPh: Unlocking Mitochondrial Apoptosis Insights; this article expands on core mechanistic principles and standardizes usage parameters.

Conclusion & Outlook

Q-VD-OPh’s irreversible, broad-spectrum caspase inhibition has transformed apoptosis research, enabling precise dissection of cell death pathways and supporting disease modeling in neurodegeneration and oncology. Its robust cell- and brain-permeability, coupled with defined IC₅₀ profiles and stability, make it a tool of choice for both in vitro and in vivo studies. Future work may explore combinatorial strategies with BAK/BAX activators (Sekar et al., 2022) or emerging cell death modulators. For authoritative protocols and product specifics, consult the Q-VD-OPh product page.